Cracking the code of therapeutic failure in inflammatory rheumatic diseases: collaborative pathways bridging academia, industry, and patient-centric innovation

Annals of the Rheumatic Diseases 2026 Open access

Read full text
Authors: Kenneth F. Baker, Elena Nikiphorou, Giulio Cavalli, Fabiana Ganz, Martin Hegen, Lauren Reinke-Breen, Mohamed Sharaf, Annette H.M. van der Helm-van Mil, Johannes W.J. Bijlsma, Iain McInnes
DOI: 10.1016/j.ard.2025.12.007
Cited by: 2
References: 32

Abstract

Close collaboration between academia and industry has formed the cornerstone of a therapeutic revolution in the management and clinical outcomes of patients living with inflammatory rheumatic musculoskeletal diseases (RMDs), driven by early diagnosis, treat-to-target strategies, and novel targeted therapies [1]. However, despite these remarkable advances, disease control can often be suboptimal for many patients, including partial or complete failure of clinical response, or secondary loss of efficacy even after extended periods of drug-induced remission.

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Biosimilars and Bioanalytical Methods Spondyloarthritis Studies and Treatments

Publication details

Journal / source
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Volume
85
Issue
6
Pages
984–990
Publication date
17 February 2026
Language
EN